Skip to content

Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis

Ultra-sound Guided Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Joint Osteoarthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03326544
Enrollment
56
Registered
2017-10-31
Start date
2017-09-01
Completion date
2018-09-30
Last updated
2020-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Knee Joint Osteoarthritis

Brief summary

Knee osteoarthritis, as a progressive disease is one of the most common causes of pain, motor disorder and disability in the elderly. By increasing age, the cartilage is eroded and endures degenerative changes due to physiological and biomechanical changes as well as metabolic effects and trauma . Non-surgical interventions for pain control of knee osteoarthritis include weight loss, exercise, changes in daily activities, physiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics .However ,the intra-articular injection is recently recommended by many studies such as corticosteroids, hyaluronic acid, Growth hormone, dextrose ,and platelet rich plasma. Intra-articular injection of platelets are activated and undergo degranulation, releasing a range of growth factors, including transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor, vascular endothelial growth factors, epidermal growth factors and basic fibroblast growth factor 2. These growth factors are thought to activate a variety of signaling pathways, which promote healing of bone and soft tissue.Also,some minimally invasive therapeutic options have been effective in pain relieve in KA, such as ultrasound-guided saphenous nerve block .

Detailed description

The aim of this study is to compare the efficacy of ultrasound guided saphenous nerve block versus platelet rich plasma injection in the management of chronic pain in patients with knee OA. This study will be conducted to evaluate which modality is more effective.

Interventions

OTHERSaphenous nerve block group

Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg

OTHERPlatelet rich plasma group

Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who are not competent to understand the study protocol * Radiographic evidence of OA of knee of 2nd degree. * Chronic pain for at least 6 months prior to study entry (day 0). * Pain relief not achieved with conservative therapies during the last 6 months

Exclusion criteria

* Patient refusal. * Bleeding disorders. * Coagulation disorders. * Local skin infection * Current other problem in the affected extremity . * Psychiatric disorders affecting co-operation of the patient . * Previous chronic opioid use. * Intra articular knee injection within previous three months. * History of traumatic arthropathy. * History of neuropathic arthropathy. * Allergy or hypersensitivity to any of the study medication. * Any condition that could interfere with the interpretation of the outcome assessments. * Pregnancy * Lactating women. * low back pain due to central cause.

Design outcomes

Primary

MeasureTime frameDescription
Pain scoresFor 6 months after interventionThe severity of pain will be assessed using a visual analog scale (VAS)

Secondary

MeasureTime frameDescription
Quality of life (QOL)For 6 months after interventionis evaluated using the Western Ontario and MC Master universities (WOMAC) index of osteoarthritis

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026